Novo Nordisk A/S (NVO) to Release Earnings on Thursday

Novo Nordisk A/S (NYSE:NVO) is scheduled to be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Novo Nordisk A/S to post earnings of $0.77 per share for the quarter. Novo Nordisk A/S has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. On average, analysts expect Novo Nordisk A/S to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $126.20 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a market cap of $566.33 billion, a price-to-earnings ratio of 46.65, a PEG ratio of 2.09 and a beta of 0.41. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The stock’s 50 day moving average price is $126.72 and its 200 day moving average price is $111.64.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s payout ratio is 49.17%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.